[{"id":"d5846c08-820b-47a2-8d52-f5f60a390316","acronym":"","url":"https://clinicaltrials.gov/study/NCT03614858","created_at":"2021-01-18T17:45:53.100Z","updated_at":"2024-07-02T16:35:27.846Z","phase":"Phase 1/2","brief_title":"CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.","source_id_and_acronym":"NCT03614858","lead_sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CART-19/22"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-29"},{"id":"5d1c9e72-e720-4cd7-bb36-31e3a019a2eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03468153","created_at":"2021-01-18T17:05:30.165Z","updated_at":"2024-07-02T16:37:12.902Z","phase":"Phase 1/2","brief_title":"Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma","source_id_and_acronym":"NCT03468153","lead_sponsor":"Ruijin Hospital","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CART-19/22"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2018-03-20"}]